Ibogaine therapy shows a definite promise in the treatment of substance use disorder. In general, ibogaine can be administered safely and without incident, especially when done with proper preparation and supervision. However, there two interrelated issues have stood in the way of further development of ibogaine as a prescription treatment: the lack of clinical research, and the issue of safety.
Phase 1 safety trials funded by the National Institute on Health (NIH) found that ibogaine is not neurotoxic. However, because of ibogaine’s systemic effects,
there are certain contraindicated conditions that can pose serious health risks if not identified during a careful screening process.